WO2020175957A1 - Composés dérivés d'amide de pirazole et leur utilisation - Google Patents
Composés dérivés d'amide de pirazole et leur utilisation Download PDFInfo
- Publication number
- WO2020175957A1 WO2020175957A1 PCT/KR2020/002897 KR2020002897W WO2020175957A1 WO 2020175957 A1 WO2020175957 A1 WO 2020175957A1 KR 2020002897 W KR2020002897 W KR 2020002897W WO 2020175957 A1 WO2020175957 A1 WO 2020175957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- amide derivative
- optical isomer
- derivative compound
- Prior art date
Links
- 0 CC(C*)C(C)N Chemical compound CC(C*)C(C)N 0.000 description 2
- CBAVGKAYASDBOE-UHFFFAOYSA-N CCOC(C(CC(Cc1cc(C)ccc1)=O)=O)=O Chemical compound CCOC(C(CC(Cc1cc(C)ccc1)=O)=O)=O CBAVGKAYASDBOE-UHFFFAOYSA-N 0.000 description 1
- LHQOEUKLGSWCBR-UHFFFAOYSA-N COc(cc1)ncc1NC(c1cc(Cc2cc(Cl)ccc2)n[nH]1)=O Chemical compound COc(cc1)ncc1NC(c1cc(Cc2cc(Cl)ccc2)n[nH]1)=O LHQOEUKLGSWCBR-UHFFFAOYSA-N 0.000 description 1
- JQNMIXCNVCPRHN-UHFFFAOYSA-N COc1ccc(Cc2n[nH]c(C(Nc3cccc(F)c3)=O)c2)cc1 Chemical compound COc1ccc(Cc2n[nH]c(C(Nc3cccc(F)c3)=O)c2)cc1 JQNMIXCNVCPRHN-UHFFFAOYSA-N 0.000 description 1
- KSRJGJIAUJRWRV-UHFFFAOYSA-N C[n]1nc(Cc(cc2)ccc2Cl)cc1C(Nc(c(OC)c1)ccc1OC)=O Chemical compound C[n]1nc(Cc(cc2)ccc2Cl)cc1C(Nc(c(OC)c1)ccc1OC)=O KSRJGJIAUJRWRV-UHFFFAOYSA-N 0.000 description 1
- SJRRJUXHPWIIAQ-UHFFFAOYSA-N O=C(c1cc(Cc(cc2)ccc2Cl)n[nH]1)Nc1ncccc1 Chemical compound O=C(c1cc(Cc(cc2)ccc2Cl)n[nH]1)Nc1ncccc1 SJRRJUXHPWIIAQ-UHFFFAOYSA-N 0.000 description 1
- MZJORNGWRMQYPW-UHFFFAOYSA-N O=C(c1cc(Cc(cc2)ccc2F)n[nH]1)Nc1ccc(C(F)(F)F)cc1 Chemical compound O=C(c1cc(Cc(cc2)ccc2F)n[nH]1)Nc1ccc(C(F)(F)F)cc1 MZJORNGWRMQYPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a pyrazole amide derivative compound and its use.
- [16] and 11 2 are each independently or 0-04 alkyl.
- a pharmaceutically acceptable salt refers to a salt commonly used in the pharmaceutical industry, for example, an inorganic ion salt made of calcium, potassium, sodium and magnesium; hydrochloric acid, nitric acid, phosphoric acid, Inorganic acid salts prepared from bromic acid, iodic acid, perchloric acid and sulfuric acid; acetic acid, trifluoroacetic acid, citric acid, maleic acid, 2020/175957 1»(:1 ⁇ 1 ⁇ 2020/002897 Succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucu Organic acid salts made of Ronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, hydroiodic acid, etc.; methanesulfonic acid, ethanes
- the present invention provides a use of a pyrazole amide derivative compound represented by the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition of the present invention may contain one or more active ingredients that exhibit the same or similar drug efficacy.
- Silver TBS-T buffer (40 mM Tris-HCl pH 7.4, 25 mM NaCl, 0.1% Tween-20) was added with 5% non-fat dry milk or 5% bovine serum albumin to inhibit non-specific binding with antibodies. The reaction was carried out on a shaker for 1 hour. After that, the blocking solution was reacted with an antibody for 2 hours at room temperature, and washed 5 times with TBS-T buffer for 5 minutes each, followed by HRP-conjugated reaction with the primary antibody. The secondary antibody was added to the blocking solution and reacted for 2 hours under the same conditions as the primary antibody. After washing 5 times with TBS-T buffer for 5 minutes each, the film was sensitized using an ECL system in a dark room to observe the expression pattern of each protein.
Abstract
La présente invention concerne un composé dérivé possédant une structure d'amide de pirazole, un énantiomère de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci. Selon la présente invention, le composé dérivé d'amide de pyrazole, l'énantiomère de celui-ci et le sel pharmaceutiquement acceptable de celui-ci, en inhibant la mitsugumine 53 (MG53), peuvent augmenter la sécrétion d'insuline, et même lorsqu'ils sont pris sur une longue période, peuvent abaisser les taux de glycémie très efficacement sans induire d'hypoglycémie, tout en ayant une fonction de protection sur les cellules bêta pancréatiques, et en même temps, résoudre de façon spectaculaire le problème de prise de poids et de résistance à l'insuline.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0023970 | 2019-02-28 | ||
KR20190023970 | 2019-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020175957A1 true WO2020175957A1 (fr) | 2020-09-03 |
Family
ID=72239640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/002897 WO2020175957A1 (fr) | 2019-02-28 | 2020-02-28 | Composés dérivés d'amide de pirazole et leur utilisation |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102396602B1 (fr) |
WO (1) | WO2020175957A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008008286A2 (fr) * | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Pyrazoles substitués servant d'antagonistes des récepteurs de la ghréline |
WO2008149379A2 (fr) * | 2007-06-06 | 2008-12-11 | Torrent Pharmaceuticals Ltd. | Nouveaux composés |
US20100190979A1 (en) * | 2005-11-28 | 2010-07-29 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
KR20140029517A (ko) * | 2011-06-09 | 2014-03-10 | 에프. 호프만-라 로슈 아게 | 피라졸 유도체 |
WO2016027253A1 (fr) * | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utilisés comme inhibiteurs de la rip1 kinase en tant que médicaments |
-
2020
- 2020-02-28 WO PCT/KR2020/002897 patent/WO2020175957A1/fr active Application Filing
- 2020-02-28 KR KR1020200025017A patent/KR102396602B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100190979A1 (en) * | 2005-11-28 | 2010-07-29 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
WO2008008286A2 (fr) * | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Pyrazoles substitués servant d'antagonistes des récepteurs de la ghréline |
WO2008149379A2 (fr) * | 2007-06-06 | 2008-12-11 | Torrent Pharmaceuticals Ltd. | Nouveaux composés |
KR20140029517A (ko) * | 2011-06-09 | 2014-03-10 | 에프. 호프만-라 로슈 아게 | 피라졸 유도체 |
WO2016027253A1 (fr) * | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utilisés comme inhibiteurs de la rip1 kinase en tant que médicaments |
Also Published As
Publication number | Publication date |
---|---|
KR20200105443A (ko) | 2020-09-07 |
KR102396602B1 (ko) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108929263B (zh) | 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途 | |
JP3743520B2 (ja) | エンドセリンの活性を調節するスルホンアミド及びそれらの誘導体 | |
DE60034605T2 (de) | Sulfonamide und deren Derivate als Modulatoren der Endothelin-Aktivität | |
US7439374B2 (en) | Azabenzofuran substituted thioureas; inhibitors of viral replication | |
JP2003176288A (ja) | エンドテリン介在障害治療用のスルホンアミド類 | |
JP2008208143A (ja) | エンドテリン介在障害治療用のスルホンアミド類 | |
KR20090018593A (ko) | 세포괴사 저해제로서의 인돌 및 인다졸 화합물 | |
DE60220255T2 (de) | N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung | |
MX2011006239A (es) | Analogos ciclicos de peptido de 4-amino-4-oxobutanoilo, inhibidores de replica viral. | |
AU2008257158A1 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents | |
CA3123215C (fr) | Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs | |
US9000029B2 (en) | Proline sulfonamide derivatives as orexin receptor antagonists | |
TW202003472A (zh) | 鈣蛋白酶(calpain)調節劑及其醫療用途 | |
EP4031245A1 (fr) | Inhibiteurs hétéroaryles de la kallicréine plasmatique | |
CA2954724A1 (fr) | Pyridinones substitues par phenyle et acide tertbutylacetique a effet anti-vih | |
KR20120013266A (ko) | 세포괴사 저해제로서의 인돌 및 인다졸 화합물 | |
EA037264B1 (ru) | Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство | |
CN105764884B (zh) | 用于治疗代谢疾病的ppar-节制性化合物 | |
CN107151236A (zh) | 一种2,3-环氧丁二酰衍生物及其制备方法和用途 | |
WO2020175957A1 (fr) | Composés dérivés d'amide de pirazole et leur utilisation | |
CA3088968C (fr) | Derive de dihydro-indolizinone | |
CA3174321A1 (fr) | Derives d'indazole utiles en tant qu'inhibiteurs de sarm1 | |
TW200800905A (en) | Substituted 1-amino-4-phenyldihydroisoquinolines, process for their preparation, their use as medicament, and medicament comprising them | |
WO2005123073A1 (fr) | Composes marins possedant des proprietes bloquant les canaux calciques, destines au traitement de maladies cognitives ou neurodegeneratives | |
CN114539129A (zh) | 烯丙胺类双功能化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20763583 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20763583 Country of ref document: EP Kind code of ref document: A1 |